Chabiotech Co.,Ltd. (KOSDAQ:085660)

Market Cap	923.23B
Revenue (ttm)	1.12T
Net Income (ttm)	-14.26B
Shares Out	76.43M
EPS (ttm)	-255.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	219,484
Average Volume	481,783
Open	12,200
Previous Close	12,230
Day's Range	11,990 - 12,200
52-Week Range	9,260 - 18,500
Beta	0.42
RSI	60.74
Earnings Date	Aug 13, 2025

About Chabiotech

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and developm...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 278
• Stock Exchange: KOSDAQ
• Ticker Symbol: 085660

Financial Performance

In 2024, Chabiotech's revenue was 1.05 trillion, an increase of 9.55% compared to the previous year's 953.95 billion. Losses were -8.05 billion, -4.48% less than in 2023.